However, it is not clear to date from clinical data whether AML patient subgroups characterized by different combinations of molecular markers, such as IDH1/2, TET2, DNMT3A, and ASXL1, have different outcomes after allo-HSCT, since the number of transplanted patients in reported studies are relatively small. The gene discussed is ASXL1; the disease is acute myeloid leukemia.